---
schema_version: "secwatch.filing_event.v1"
accession: "0001161697-21-000375"
form_type: "8-K"
ticker: "KRMD"
cik: "0000704440"
company_name: "KORU Medical Systems, Inc."
filed_at: "2021-08-11T23:59:59+00:00"
generated_at: "2026-06-29T15:48:25.296748+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# KORU Medical Q2 net revenue $5.5M; net loss $1.1M; sequential growth of 2%

## Summary
- Net revenue of $5.5 million, down 28.3% YoY but up 2% sequentially.
- Gross margin 58.1%, down 5.6 ppts YoY due to lower volumes.
- Net loss of $1.1 million ($0.03 diluted loss per share).
- Non-GAAP adjusted EBITDA of $(0.3) million vs $1.8 million in Q2 2020.
- Mid-single-digit growth in domestic immunoglobulin market and specialty pharmacy channel indicates market recovery.

## SEC filing metadata
- accession: 0001161697-21-000375
- form_type: 8-K
- ticker: KRMD
- cik: 0000704440
- company_name: KORU Medical Systems, Inc.
- filed_at: 2021-08-11T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/704440/000116169721000375/0001161697-21-000375-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/704440/000116169721000375/form_8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001161697-21-000375
- JSON: https://secwatch.observer/filing/0001161697-21-000375.json
- Plain text: https://secwatch.observer/filing/0001161697-21-000375.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.